FrancophonIA/ELRC3.0 huggingface dataset:
English: The emulsion contains the ‘adjuvant' to enhance the immune response.
Estonian: Emulsioon sisaldab parema immuunvastuse saamiseks ka adjuvanti.
English: A flu pandemic happens when a new strain of flu virus appears that can spread easily from person to person because people have no immunity (protection) against it. A pandemic can affect most countries and regions around the world.
Estonian: Gripipandeemia tekib, kui ilmub uus gripiviiruse tüvi, mis võib kergesti levida inimeselt inimesele, sest selle vastu puudub immuunsus (kaitse).
English: Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
Estonian: Pumarix pandeemilise gripi vaktsiin (H5N1) (inaktiveeritud purustatud viirus, adjuveeritud)
English: Why has Pumarix been approved?
Estonian: Miks Pumarix heaks kiideti?
English: The most common side effects with Pumarix (seen in more than 1 patient in 10) are headache, joint pain, muscle ache, pain at injection site and fatigue (tiredness).
Estonian: Pumarixi kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peavalu, liigesevalu, lihasvalu süstekoha valulikkus ja väsimus.
English: Before use, the vaccine will be made up by mixing together a suspension that contains the virus particles with an emulsion.
Estonian: Vaktsiin valmistatakse enne kasutamist, segades omavahel viiruseosakesi sisaldava suspensiooni ja emulsiooni.
English: People who have previously been vaccinated with a vaccine that contains the same adjuvant (a substance added to enhance the immune response) and a flu strain similar to the one causing the pandemic will only need one single dose.
Estonian: Patsientidele, keda on eelnevalt vaktsineeritud sama adjuvanti (aine, mis aitab tugevdada immuunvastust) sisaldava vaktsiiniga pandeemiat põhjustava tüvega sarnase gripitüve vastu, manustatakse ainult üks annus.
English: Pumarix is a vaccine to protect against ‘pandemic' flu.
Estonian: Pumarix on vaktsiin, mida kasutatakse pandeemilise gripi eest kaitsmiseks.
English: What is the risk associated with Pumarix?
Estonian: Mis riskid Pumarixiga kaasnevad?
English: During a pandemic, the virus strain in the vaccine will have to be replaced by the strain causing the pandemic before the vaccine can be used.
Estonian: Pandeemia ajal tuleb vaktsiinis sisalduv viirusetüvi enne vaktsiini kasutamist asendada pandeemiat põhjustava tüvega.
English: What information is still awaited for Pumarix?
Estonian: Mis teavet Pumarixi kohta veel oodatakse?
English: In the first study, the immunogenicity of Pumarix was shown to be comparable to that of the comparator vaccine.
Estonian: Esimeses uuringus oli Pumarixi immunogeensus võrreldav võrdlusravimi immunogeensusega.
English: The second study showed that Pumarix was able to trigger the production of antibodies to a level high enough to meet CHMP criteria.
Estonian: Teine uuring näitas, et vastavalt inimravimite komitee kriteeriumitele tekitas Pumarix antikehi piisavalt.
English: The vaccine has been authorised under ‘exceptional circumstances'.
Estonian: Vaktsiinile anti müügiluba erandkorras.
English: The effects of Pumarix were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Pumarixi toimet muude katsetega.
English: How does Pumarix work?
Estonian: Kuidas Pumarix toimib?
English: What benefit has Pumarix shown during the studies?
Estonian: Milles seisneb uuringute põhjal Pumarix kasulikkus?
English: This vaccine contains small amounts of haemagglutinins (proteins from the surface) of a virus called H5N1.
Estonian: See vaktsiin sisaldab väheses koguses viiruse H5N1 hemaglutiniine (teatud pinnavalke).
English: This is a special type of vaccine that can be developed to help with the management of a future pandemic.
Estonian: Pumarix on imitatsioonvaktsiin ehk vaktsiini eriliik, mida saab edasi arendada tulevase pandeemia ohjeldamiseks.
English: How has Pumarix been studied?
Estonian: Kuidas Pumarixi uuriti?
English: Pumarix is a ‘mock-up' vaccine.
Estonian: Pumarix on süstitav vaktsiin.
English: How is Pumarix used?
Estonian: Kuidas Pumarixi kasutatakse?
English: What is Pumarix used for?
Estonian: Milleks Pumarixi kasutatakse?
English: Frequency “Not known”
Estonian: Esinemissagedus „teadmata“
English: Adopted at the 2-5 September 2019 PRAC
Estonian: Vastu võetud ravimiohutuse riskihindamise komitee 2.-5. septembri 2019 koosolekul
English: What you need to know before you take IMBRUVICA
Estonian: 2. Mida on vaja teada enne IMBRUVICA võtmist
English: In both cases, tTreatment with <product name> may be restarted once when the ketone values are normal and the patient's condition has stabilised.
Estonian: Mõlemal juhul Ravi <ravimi nimetus kaasaütlevas käändes> võib taasalustada, kui ketoonide sisaldus on normis ja patsiendi seisund on stabiliseerunud.
English: 2 Canagliflozin; canagliflozin, metformin; dapagliflozin; dapagliflozin, metformin; empagliflozin; empagliflozin, metformin; empagliflozin, linagliptin; ertugliflozin, metformin; ertugliflozin, sitagliptin; saxagliptin, dapagliflozin
Estonian: 2 Kanagliflosiin; kanagliflosiin, metformiin; dapagliflosiin; dapagliflosiin, metformiin; empagliflosiin; empagliflosiin, metformiin; empagliflosiin, linagliptiin; ertugliflosiin, metformiin; ertugliflosiin, sitagliptiin; saksagliptiin, dapagliflosiin
English: Latency from the initiation of treatment with ibrutinib to the onset of ischemic central nervous vascular conditions was in the most cases after several months (more than 1 month in 78% and more than 6 months in 44% of cases) emphasizing the need for regular monitoring of patients (please see section 4.4 Cardiac arrhythmia and Hypertension and section 4.8).
Estonian: Latentsusperiood ibrutiniibiga ravi alustamisest kuni kesknärvisüsteemi isheemiliste vaskulaarsete haigusseisundite tekkeni oli enamikul juhudest mitu kuud (üle 1 kuu 78%-l ja üle 6 kuu 44%-l juhtumitest), mis rõhutab patsientide regulaarse jälgimise vajadust (vt lõik 4.4 „Südamearütmia“ ja „Hüpertensioon“ ning lõik 4.8).
English: What you need to know before you use <product name>
Estonian: 2. Mida on vaja teada enne <ravimi nimetus> võtmist
English: Footnotes:
Estonian: Joonealused märkused:
English: For ibuprofen and pseudoephedrine combinations 4.4.
Estonian: Ibuprofeeni ja pseudoefedriini kombinatsioonid 4.4.
English: Sodium-glucose co-transporter 2 (SGLT2) inhibitors2New information on the known association between SGLT2 inhibitors and diabetic ketoacidosis in surgical patients (EPITT no 19355)
Estonian: Naatriumi-glükoosi kotransporter 2 (SGLT2) inhibiitorid2uus teave SGLT2 inhibiitorite ja kirurgilistel patsientidel esineva diabeetilise ketoatsidoosi teadaoleva seose kohta (EPITT nr 19355)
English: 1 Only if the already existing AGEP ADR in section 4.8 is listed specifically for pseudoephedrine.
Estonian: 1 Üksnes juhul, kui juba olemasoleva ägeda generaliseerunud eksantematoosse pustuloosi kõrvaltoimed loetletakse lõigus 4.8 konkreetselt pseudoefedriini jaoks.
English: Treatment withdrawal and initiation of an accelerated elimination procedure may be considered taking into account patient's disease and medical history.
Estonian: Kaaluda võib ravi lõpetamise ja kiirendatud eliminatsiooniprotseduuri alustamise vajadust, arvestades patsiendi haigust ja ravi anamneesi.
English: Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment.
Estonian: Suurim risk nahareaktsioonide tekkeks patsientidel on varases ravijärgus: enamusel juhtudest tekib reaktsioon ravi esimesel kuul.
English: Tell a doctor straight away if you notice any of the following side effects: Uncommon (may affect up to 1 in 100 people): temporary episode of neurologic dysfunction caused by loss of blood flow, stroke.
Estonian: Teatage kohe arstile, kui te märkate mõnda järgmistest kõrvaltoimetest: Aeg-ajalt (võivad esineda kuni 1 inimesel 100st): verevoolu katkemisest tingitud ajutine neuroloogiline talitlushäire, insult.
English: Teriflunomide - Psoriasis (EPITT no 19366)
Estonian: Teriflunomiid - psoriaas (EPITT nr 19366)
English: A red, scaly widespread rash with bumps under the skin and blisters mainly localized on the skin folds, trunk, and upper extremities accompanied by fever at the initiation of treatment (acute generalised exanthematous pustulosis).
Estonian: Punane, ketendav ulatuslik lööve nahaaluste muhkude ja villidega, mis peamiselt esinevad nahavoltides, kehatüvel ja ülajäsemetel ja millega kaasneb palavik ravi alustamisel (äge generaliseerunud eksantematoosne pustuloos).
English: Special warnings and precautions for use Diabetic ketoacidosis
Estonian: Erihoiatused ja ettevaatusabinõud kasutamisel Diabeetiline ketoatsidoos
English: Warnings and precautions - Take special care with <product name> Skin reactions2
Estonian: „Hoiatused ja ettevaatusabinõud“ - „Eriline ettevaatus on vajalik ravimiga <ravimi nimetus>“ Nahareaktsioonid2
English: Tabulated list of adverse reactions Skin and subcutaneous tissue disorders Frequency not known: Psoriasis (including pustular psoriasis)b b: see section 4.4
Estonian: Naha ja nahaaluskoe kahjustused Esinemissagedus „teadmata“: psoriaas (sh pustuloosne psoriaas)b b: vt lõik 4.4
English: You should stop taking <product name> and seek medical attention immediately, if you develop any skin rash, lesions of the mucous membranes, blisters or other signs of allergy since this can be the first signs of a very serious skin reaction.
Estonian: Lõpetage <ravimi nimetus omastavas käändes> võtmine ja võtke kohe ühendust oma arstiga või pöörduge raviasutusse, kui teil on tekkinud nahalööve, limaskestade kahjustused, villid või muud allergianähud, sest need võivad olla väga tõsise nahareaktsiooni esimesed nähud.
English: Ibuprofen should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.
Estonian: Ibuprofeenravi tuleb katkestada raskete nahareaktsioonide esimeste nähtude ja sümptomite ilmnemisel, nt nahalööve, limaskestade kahjustused või mis tahes muu ülitundlikkuse näht.
English: Stop using <product name> if you develop these symptoms and seek medical attention immediately.
Estonian: Nende sümptomite tekkimisel lõpetage <ravimi nimetus omastavas käändes> kasutamine ja võtke kohe ühendust oma arstiga või pöörduge raviasutusse.
English: Ibrutinib - Ischaemic stroke (EPITT no 19369)
Estonian: Ibrutiniib - isheemiline insult (EPITT nr 19369)
English: New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during the use of teriflunomide.
Estonian: Terflunomiidi kasutamisel on teatatud psoriaasi (sh pustuloosse psoriaasi) esmatekkest ja varem esinenud psoriaasi halvenemisest.
English: Ibuprofen - Acute generalised exanthematous pustulosis (AGEP) (EPITT no 19409)
Estonian: Ibuprofeen - äge generaliseerunud eksantematoosne pustuloos (EPITT nr 19409)
English: For ibuprofen monotherapy or ibuprofen in combinations excluding combinations with pseudoephedrine
Estonian: Ibuprofeeni monoteraapia või ibuprofeeni kombinatsioonid, v.a kombinatsioonid pseudoefedriiniga
English: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported rarely in association with the use of NSAIDSs (see section 4.8).
Estonian: MSPVAdega (mittesteroidsed põletikuvastased ravimid) seoses on harva teatatud rasketest, mõnel juhul surmlõppega nahareaktsioonidest, sh eksfoliatiivne dermatiit, Stevensi-Johnsoni sündroom ja toksiline epidermaalne nekrolüüs (vt lõik 4.8).
English: 2 The following text should replace any current information regarding serious skin reactions in section Warnings and precautions.
Estonian: 2 Jaotise „Hoiatused ja ettevaatusabinõud“ praegune teave raskete nahareaktsioonide kohta tuleb asendada järgmise tekstiga.
English: Cases of cerebrovascular accident, transient ischaemic attack and ischaemic stroke including fatalities have been reported with the use of ibrutinib, with and without concomitant atrial fibrillation and/or hypertension.
Estonian: Ibrutiniibi kasutamisel on teatatud tsrebrovaskulaarse ataki, transitoorse isheemilise ataki ja isheemilise insuldi juhtudest (sh surmlõppega juhtumid) koos kaasuva kodade virvenduse ja/või hüpertensiooniga või ilma.
English: Uncommon: cerebrovascular accident, transient ischaemic attack, ischaemic stroke
Estonian: Närvisüsteemi häired Aeg-ajalt: tserebrovaskulaarne atakk, transitoorne isheemiline atakk, isheemiline insult
English: Severe skin reactions such as acute generalised exanthematous pustulosis (AGEP) may occur with ibuprofen and pseudoephedrine-containing products.
Estonian: Rasked nahareaktsioonid, nt äge generaliseerunud eksantematoosne pustuloos võib tekkida ibuprofeeni ja pseudoefedriini sisaldavate ravimite kasutamisel.
English: Serious skin reactions have been reported in association with <product name> treatment.
Estonian: Seoses <ravimi nimetus omastavas käändes> raviga on teatud tõsistest nahareaktsioonidest.
English: Acute generalised exanthematous pustulosis (AGEP) has been reported in relation to ibuprofen-containing products.
Estonian: Ibuprofeeni sisaldavate ravimitega seoses on teatatud ägedast generaliseerunud eksantematoossest pustuloosist.
English: Undesirable effects Tabulated list of adverse reactions Nervous system disorders
Estonian: Kõrvaltoimed Kõrvaltoimete tabel
English: Special warnings and precautions for use Skin reactions
Estonian: Erihoiatused ja ettevaatusabinõud kasutamisel Nahareaktsioonid
English: The children were followed up until the end of their second year of life.
Estonian: Lapsi jälgiti kuni nende teise eluaasta lõpuni.
English: The children were followed up for an average of around 2 years.
Estonian: Lapsi jälgiti keskmiselt ligikaudu 2 aastat.
English: The full EPAR for Synflorix can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Synflorixi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: The vaccination schedule for Synflorix depends on the age of the child and should be based on official recommendations.
Estonian: Synflorixi vaktsineerimisskeem sõltub lapse vanusest ning see peab põhinema ametlikel soovitustel.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Synflorix on 30 March 2009.
Estonian: Euroopa Komisjon andis Synflorixi müügiloa, mis kehtib kogu Euroopa Liidus, 30. märtsil 2009.
English: What measures are being taken to ensure the safe and effective use of Synflorix?
Estonian: Mis meetmed võetakse, et tagada Synflorixi ohutu ja efektiivne kasutamine?
English: The vaccine is also adsorbed (fixed) onto an aluminium compound to stimulate a better response.
Estonian: Vaktsiin on adsorbeeritud (fikseeritud) parema ravivastuse stimuleerimiseks ka alumiiniumiühendile.
English: Other information about Synflorix
Estonian: Muu teave Synflorixi kohta
English: In Europe, it is estimated that these are responsible for 56 to 90% of the cases of invasive disease caused by S. pneumoniae in children under the age of 5 years.
Estonian: Need serotüübid põhjustavad Euroopas hinnangute kohaselt 56-90% S. pneumoniae tekitatud invasiivsete haiguste juhtudest alla 5-aastastel lastel.
English: Vaccines work by ‘teaching' the immune system (the body's natural defences) to defend the body against the infection.
Estonian: Vaktsiinid n-ö õpetavad immuunsüsteemi (organismi looduslikke kaitsemehhanisme) kaitsma organismi infektsiooni eest.
English: In studies in infants and older children, although Synflorix produced a lower antibody response than the comparator vaccine, it fulfilled pre-defined criteria and was considered acceptable in this group.
Estonian: Uuringutest imikutel ja vanematel lastel nähtus, et kuigi Synflorix tekitas vähem antikehi kui võrdlusvaktsiin, täitis see eelmääratud kriteeriumid ja seda peeti selle rühma puhul vastuvõetavaks.
English: The majority of these reactions were of mild to moderate severity and were not long lasting.
Estonian: Enamik kõrvalnähte olid raskusastmelt kerged kuni mõõdukad ning mööduvad.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Synflorix have been included in the summary of product characteristics and the package leaflet.
Estonian: Synflorixi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Synflorix contains the polysaccharides from ten different types of S. pneumoniae (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F).
Estonian: Synflorix sisaldab kümmet eri tüüpi (serotüübid 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F ja 23F) S. pneumoniae polüsahhariide.
English: These polysaccharides have been purified, then conjugated (attached) to a carrier to help them to be recognised by the immune system.
Estonian: Polüsahhariidid on puhastatud ja seejärel konjugeeritud (seotud) kandeainega, et immuunsüsteem need paremini ära tunneks.
English: Invasive disease results from the bacterium spreading through the body causing serious infections such as septicaemia (blood infection), meningitis (infection of the membranes around the brain and spine) and pneumonia.
Estonian: Invasiivne haigus tekib juhul, kui bakter levib kogu organismis, põhjustades raskeid infektsioone, näiteks sepsis (nakkusveresus), meningiit (pea- ja seljaajukelme infektsioon) ja kopsupõletik.
English: • When Synflorix is given as part of a routine infant immunisation programme (when all infants in an area are vaccinated at around the same time), a course of two doses may be given 2 months apart, from the age of 6 weeks, followed by a booster dose at least 6 months later.
Estonian: • Kui Synflorixi manustatakse imikute üldise immuniseerimisprogrammi raames (kui piirkonna kõiki imikuid vaktsineeritakse ligikaudu samal ajal), võib imikutele anda kaks annust 2-kuulise vahega ning seejärel, vähemalt 6 kuud hiljem antakse võimendav annus.
English: The Agency also noted that Synflorix contains additional polysaccharides from the types of S. pneumoniae that are responsible for disease in Europe and therefore decided that Synflorix's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Amet märkis samuti, et Synflorix sisaldab täiendavaid Euroopas haigusi põhjustavate S. pneumoniae serotüüpide polüsahhariide, ning otsustas seetõttu, et Synflorixi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda vaktsiini müügiloa.
English: The most common side effects with Synflorix (which may affect more than 1 in 10 people) are pain, redness and swelling at the injection site, fever, drowsiness, irritability and loss of appetite.
Estonian: Synflorixi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on süstekoha valu, punetus ja turse ning palavik, unisus, ärrituvus ja isukaotus.
English: However, children aged under 6 months with conditions that make them more likely to catch these invasive diseases, such as those with human immunodeficiency virus (HIV) infection, sickle cell disease or spleen problems, should be given three doses followed by a booster dose.
Estonian: Alla 6 kuu vanustele lastele, kes on mõne haigusseisundi tõttu vastuvõtlikumad kõnealustele invasiivsetele haigustele, näiteks inimese immuunpuudulikkuse viirusega (HIV) nakatunud, sirprakkaneemiaga või põrnaprobleemidega lapsed, tuleb manustada kolm annust ja seejärel võimendav annus.
English: What is Synflorix and what is it used for?
Estonian: Mis on Synflorix ja milleks seda kasutatakse?
English: Additional studies looked at the effects of booster vaccinations and vaccinations in older infants and children.
Estonian: Täiendavates uuringutes vaadeldi kordusvaktsineerimise (võimendav annus) toimet ning vanemate imikute ja laste vaktsineerimist.
English: This is a summary of the European public assessment report (EPAR) for Synflorix.
Estonian: See on vaktsiini Synflorix Euroopa avaliku hindamisaruande kokkuvõte.
English: The vaccine is given by injection into the thigh muscle in infants or into the shoulder muscle in young children.
Estonian: Vaktsiin manustatakse süstina imikutel reielihasesse ja väikelastel õlalihasesse.
English: In particular, two clinical studies in children aged 2 to 5 years investigated the ability of Synflorix to produce antibodies in this age group compared with other age groups.
Estonian: Täpsemalt uuriti kahes kliinilises uuringus Synflorixi võimet tekitada antikehi 2-5-aastastel lastel võrreldes teiste vanuserühmadega.
English: A fourth (‘booster') dose is recommended at least 6 months after the third dose, preferably when the child is between 12 and 15 months of age.
Estonian: Neljas (võimendav) annus on soovitatav manustada vähemalt 6 kuud pärast kolmandat annust, eelistatavalt 12. ja 15. elukuu vahel.
English: Pneumococcal polysaccharide conjugate vaccine (adsorbed)
Estonian: Synflorix pneumokokk-polüsahhariidi konjugaatvaktsiin (adsorbeeritud)
English: Synflorix was also investigated in a large study involving around 24,000 children aged between 6 and 16 weeks that focussed mainly on the vaccine's benefit in preventing community acquired pneumonia.
Estonian: Synflorixi uuriti ka ulatuslikus uuringus, milles osales ligikaudu 24 000 last vanuses 6-16 nädalat ja milles keskenduti põhiliselt vaktsiini efektiivsusele keskkonnatekkese kopsupõletiku ennetamisel.
English: The response to Synflorix in 2 to 5 year olds was similar to the younger age group, with better results in children who received two doses.
Estonian: 2-5-aastaste laste ravivastus Synflorixile oli sarnane nooremas vanuserühmas täheldatud ravivastusega ning kaks annust saanud lastel olid tulemused paremad.
English: Why is Synflorix approved?
Estonian: Miks Synflorix heaks kiideti?
English: Synflorix must not be used in children who have a high fever, but it can be given in children who have a mild infection such as a cold. For the full list of restrictions, see the package leaflet.
Estonian: Synflorixi ei tohi kasutada kõrge palavikuga lastel, kuid seda võib anda lastele, kellel on kerge infektsioon, näiteks kerge ülemiste hingamisteede infektsioon.
English: It is not intended to provide practical advice on how to use Synflorix.
Estonian: Hindamisaruandes ei anta Synflorixi kasutamise praktilisi nõuandeid.
English: The percentage of children who had bacterial pneumonia was 2.3% (240 out of over 10,000) among those given Synflorix compared with 3% (304 out of over 10,000) among those given the comparator.
Estonian: Synflorixi rühmas haigestus bakteriaalsesse kopsupõletikku 2,3% (240 patsienti enam kui 10 000st) patsientidest ja võrdlusvaktsiini rühmas 3% (304 patsienti enam kui 10 000st) patsientidest.
English: Synflorix was effective in protecting against invasive disease: no cases were seen among the 10,000 children given three doses of Synflorix and a booster dose, one case occurred among the 10,000 children given two doses of Synflorix and a booster dose and 12 cases occurred in 10,000 children given the comparator vaccine.
Estonian: Synflorix oli efektiivne invasiivsete haiguste eest kaitsmisel: nende 10 000 lapse seas, kes said kolm annust Synflorixi ja võimendava annuse, ei esinenud ühtegi haigusjuhtu; nende 10 000 lapse seas, kes said kaks annust Synflorixi ja võimendava annuse, oli üks haigusjuht ja nende 10 000 lapse seas, kes said võrdlusvaktsiini, oli 12 haigusjuhtu.
English: Synflorix is a vaccine that protects against infections caused by S. pneumoniae.
Estonian: Synflorix on vaktsiin, mis kaitseb S. pneumoniae põhjustatud infektsioonide eest.
English: The ability of Synflorix to trigger the production of antibodies (immunogenicity) was assessed in one main study involving 1,650 healthy infants aged between 6 and 12 weeks.
Estonian: Synflorixi omadust tekitada antikehi (immunogeensust) uuriti ühes põhiuuringus, milles osales 1650 tervet imikut vanuses 6-12 nädalat.